{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:31:05Z","timestamp":1773333065957,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00405-022-07809-6","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T03:02:30Z","timestamp":1672110150000},"page":"2497-2509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tumor volume reduction after induction chemotherapy with gemcitabine plus cisplatin in nasopharyngeal carcinoma"],"prefix":"10.1007","volume":"280","author":[{"given":"Qian","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangfang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8457-3994","authenticated-orcid":false,"given":"Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"issue":"12","key":"7809_CR1","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY et al (2019) Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 381(12):1124\u20131135. https:\/\/doi.org\/10.1056\/NEJMoa1905287","journal-title":"N Engl J Med"},{"issue":"2","key":"7809_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/jco.2008.18.1545","volume":"27","author":"EP Hui","year":"2009","unstructured":"Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK et al (2009) Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 27(2):242\u2013249. https:\/\/doi.org\/10.1200\/jco.2008.18.1545","journal-title":"J Clin Oncol"},{"issue":"11","key":"7809_CR3","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/s1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY et al (2016) Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 17(11):1509\u20131520. https:\/\/doi.org\/10.1016\/s1470-2045(16)30410-7","journal-title":"Lancet Oncol"},{"issue":"2","key":"7809_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/hed.26932","volume":"44","author":"T Liu","year":"2022","unstructured":"Liu T, Dai S, Zhang H, Zhong X, Ding Z, Ma X (2022) The best choice of induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma: Bayesian network meta-analysis. Head Neck 44(2):518\u2013529. https:\/\/doi.org\/10.1002\/hed.26932","journal-title":"Head Neck"},{"issue":"8","key":"7809_CR5","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1002\/hed.26699","volume":"43","author":"H Guan","year":"2021","unstructured":"Guan H, He Y, Su Y, Wei Z, Liu Z, Wang J et al (2021) Assessment of different induction chemotherapy regimens in locally advanced nasopharyngeal carcinoma: meta-analysis. Head Neck 43(8):2332\u20132341. https:\/\/doi.org\/10.1002\/hed.26699","journal-title":"Head Neck"},{"issue":"3","key":"7809_CR6","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00405-021-06940-0","volume":"279","author":"M Tang","year":"2022","unstructured":"Tang M, Jia Z, Zhang J (2022) The safety and efficacy of gemcitabine and cisplatin (GP)-based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis. Eur Arch Otorhinolaryngol 279(3):1561\u20131572. https:\/\/doi.org\/10.1007\/s00405-021-06940-0","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"7809_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.105158","volume":"114","author":"SK Chan","year":"2021","unstructured":"Chan SK, Chan SY, Tong CC, Lam KO, Kwong DL, Leung TW et al (2021) Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinoma: a pooled analysis of two prospective studies. Oral Oncol 114:105158. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.105158","journal-title":"Oral Oncol"},{"key":"7809_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.682271","volume":"11","author":"CD Zhang","year":"2021","unstructured":"Zhang CD, Li M, Hong YJ, Cai ZM, Huang KC, Lin ZX et al (2021) Development and validation of prognostic nomograms based on gross tumor volume and cervical nodal volume for nasopharyngeal carcinoma patients with concurrent chemoradiotherapy. Front Oncol 11:682271. https:\/\/doi.org\/10.3389\/fonc.2021.682271","journal-title":"Front Oncol"},{"issue":"3","key":"7809_CR9","doi-asserted-by":"publisher","first-page":"861","DOI":"10.4143\/crt.2017.237","volume":"50","author":"QY Chen","year":"2018","unstructured":"Chen QY, Guo SY, Tang LQ, Lu TY, Chen BL, Zhong QY et al (2018) Combination of tumor volume and Epstein-Barr virus DNA improved prognostic stratification of stage II nasopharyngeal carcinoma in the intensity modulated radiotherapy era: a large-scale cohort study. Cancer Res Treat 50(3):861\u2013871. https:\/\/doi.org\/10.4143\/crt.2017.237","journal-title":"Cancer Res Treat"},{"key":"7809_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104897","volume":"110","author":"H Yang","year":"2020","unstructured":"Yang H, Liu Y, Zhang R, Ye Y, Chen Q, Qin Q et al (2020) Prognostic value of the tumor volume reduction rate after neoadjuvant chemotherapy in patients with locoregional advanced nasopharyngeal carcinoma. Oral Oncol 110:104897. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.104897","journal-title":"Oral Oncol"},{"issue":"2","key":"7809_CR11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.4143\/crt.2015.081","volume":"48","author":"H Lee","year":"2016","unstructured":"Lee H, Ahn YC, Oh D, Nam H, Noh JM, Park SY (2016) Tumor volume reduction rate during adaptive radiation therapy as a prognosticator for nasopharyngeal cancer. Cancer Res Treat 48(2):537\u2013545. https:\/\/doi.org\/10.4143\/crt.2015.081","journal-title":"Cancer Res Treat"},{"key":"7809_CR12","doi-asserted-by":"publisher","first-page":"8001","DOI":"10.12659\/msm.909736","volume":"24","author":"L Zheng","year":"2018","unstructured":"Zheng L, Liao W, Xu P, Li B, Wen H, Zhang S (2018) Tumor volume reduction after gemcitabine plus cisplatin induction chemotherapy in locally advanced nasopharyngeal cancer: comparison with paclitaxel and cisplatin regimens. Med Sci Monit 24:8001\u20138008. https:\/\/doi.org\/10.12659\/msm.909736","journal-title":"Med Sci Monit"},{"issue":"2","key":"7809_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4143\/crt.2018.250","volume":"51","author":"L Wang","year":"2019","unstructured":"Wang L, Wu Z, Xie D, Zeng R, Cheng W, Hu J et al (2019) Reduction of target volume and the corresponding dose for the tumor regression field after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Cancer Res Treat 51(2):685\u2013695. https:\/\/doi.org\/10.4143\/crt.2018.250","journal-title":"Cancer Res Treat"},{"issue":"8","key":"7809_CR14","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1007\/s00405-020-06477-8","volume":"278","author":"S Li","year":"2021","unstructured":"Li S, Shen L (2021) The change in tumor volume after induction chemotherapy with docetaxel plus cisplatin in 259 nasopharyngeal carcinoma patients. Eur Arch Otorhinolaryngol 278(8):3027\u20133035. https:\/\/doi.org\/10.1007\/s00405-020-06477-8","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"7809_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.oraloncology.2018.08.016","volume":"85","author":"PJ Li","year":"2018","unstructured":"Li PJ, Mo HY, Luo DH, Hu WH, Jin T (2018) The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era. Oral Oncol 85:95\u2013100. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.08.016","journal-title":"Oral Oncol"},{"issue":"2","key":"7809_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.radonc.2008.02.003","volume":"87","author":"AW Lee","year":"2008","unstructured":"Lee AW, Lau KY, Hung WM, Ng WT, Lee MC, Choi CW et al (2008) Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiother Oncol 87(2):204\u2013210. https:\/\/doi.org\/10.1016\/j.radonc.2008.02.003","journal-title":"Radiother Oncol"},{"key":"7809_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3389\/fmed.2018.00234","volume":"5","author":"A Blank","year":"2018","unstructured":"Blank A, Roberts DE 2nd, Dawson H, Zlobec I, Lugli A (2018) Tumor heterogeneity in primary colorectal cancer and corresponding metastases. Does the apple fall far from the tree? Front Med (Lausanne) 5:234. https:\/\/doi.org\/10.3389\/fmed.2018.00234","journal-title":"Front Med (Lausanne)"},{"key":"7809_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215355","author":"P Baumeister","year":"2021","unstructured":"Baumeister P, Zhou J, Canis M, Gires O (2021) Epithelial-to-mesenchymal transition-derived heterogeneity in head and neck squamous cell carcinomas. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13215355","journal-title":"Cancers (Basel)"},{"issue":"11","key":"7809_CR19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1097\/jcma.0000000000000178","volume":"82","author":"YH Liu","year":"2019","unstructured":"Liu YH, Lin YS (2019) Platelet-lymphocyte and neutrophil-lymphocyte ratios: predictive factors of response and toxicity for docetaxel-combined induction chemotherapy in advanced head and neck cancers. J Chin Med Assoc 82(11):849\u2013855. https:\/\/doi.org\/10.1097\/jcma.0000000000000178","journal-title":"J Chin Med Assoc"},{"issue":"4","key":"7809_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2217\/imt-2021-0149","volume":"14","author":"H Ghebeh","year":"2022","unstructured":"Ghebeh H, Elshenawy MA, AlSayed AD, Al-Tweigeri T (2022) Peripheral blood eosinophil count is associated with response to chemoimmunotherapy in metastatic triple-negative breast cancer. Immunotherapy 14(4):189\u2013199. https:\/\/doi.org\/10.2217\/imt-2021-0149","journal-title":"Immunotherapy"},{"issue":"11","key":"7809_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/cac2.12100","volume":"40","author":"R Tan","year":"2020","unstructured":"Tan R, Phua SKA, Soong YL, Oon LLE, Chan KS, Lucky SS et al (2020) Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma. Cancer Commun (Lond) 40(11):564\u2013585. https:\/\/doi.org\/10.1002\/cac2.12100","journal-title":"Cancer Commun (Lond)"},{"issue":"2","key":"7809_CR22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/jnci\/djaa090","volume":"113","author":"G Floris","year":"2021","unstructured":"Floris G, Richard F, Hamy AS, Jongen L, Wildiers H, Ardui J et al (2021) Body mass index and tumor-infiltrating lymphocytes in triple-negative breast cancer. J Natl Cancer Inst 113(2):146\u2013153. https:\/\/doi.org\/10.1093\/jnci\/djaa090","journal-title":"J Natl Cancer Inst"},{"key":"7809_CR23","doi-asserted-by":"publisher","first-page":"175883592097005","DOI":"10.1177\/1758835920970050","volume":"12","author":"L Huang","year":"2020","unstructured":"Huang L, Sim AYL, Wu Y, Liang Z, Li K, Du Y et al (2020) Lactate dehydrogenase kinetics predict chemotherapy response in recurrent metastatic nasopharyngeal carcinoma. Ther Adv Med Oncol 12:1758835920970050. https:\/\/doi.org\/10.1177\/1758835920970050","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"7809_CR24","doi-asserted-by":"publisher","first-page":"11348","DOI":"10.1038\/s41598-021-91049-x","volume":"11","author":"Y Li","year":"2021","unstructured":"Li Y, Zhang J, Wang B, Zhang H, He J, Wang K (2021) A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer. Sci Rep 11(1):11348. https:\/\/doi.org\/10.1038\/s41598-021-91049-x","journal-title":"Sci Rep"},{"key":"7809_CR25","doi-asserted-by":"publisher","DOI":"10.5551\/jat.63285","author":"T Maruhashi","year":"2021","unstructured":"Maruhashi T, Kajikawa M, Kishimoto S, Takaeko Y, Yamaji T, Harada T et al (2021) Serum potassium levels of 4.5 to less than 5.0 mmol\/L are associated with better vascular function. J Atheroscler Thromb. https:\/\/doi.org\/10.5551\/jat.63285","journal-title":"J Atheroscler Thromb"},{"key":"7809_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.757456","volume":"11","author":"J Zhou","year":"2021","unstructured":"Zhou J, Bai J, Yue Y, Chen X, Lange T, You D et al (2021) Association of hypokalemia incidence and better treatment response in NSCLC patients: a meta-analysis and systematic review on anti-EGFR targeted therapy clinical trials. Front Oncol 11:757456. https:\/\/doi.org\/10.3389\/fonc.2021.757456","journal-title":"Front Oncol"},{"issue":"1","key":"7809_CR27","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1186\/s12885-018-5098-7","volume":"18","author":"A Ghoshal","year":"2018","unstructured":"Ghoshal A, Garmo H, Hammar N, Jungner I, Malmstr\u00f6m H, Walldius G et al (2018) Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival? BMC Cancer 18(1):1169. https:\/\/doi.org\/10.1186\/s12885-018-5098-7","journal-title":"BMC Cancer"},{"key":"7809_CR28","doi-asserted-by":"publisher","unstructured":"(1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med, 329(14): 987\u201394. https:\/\/doi.org\/10.1056\/nejm199309303291402","DOI":"10.1056\/nejm199309303291402"},{"key":"7809_CR29","doi-asserted-by":"publisher","first-page":"22326","DOI":"10.1038\/srep22326","volume":"6","author":"GQ Zhou","year":"2016","unstructured":"Zhou GQ, Ren XY, Mao YP, Chen L, Sun Y, Liu LZ et al (2016) Prognostic implications of dynamic serum lactate dehydrogenase assessments in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Sci Rep 6:22326. https:\/\/doi.org\/10.1038\/srep22326","journal-title":"Sci Rep"},{"issue":"16","key":"7809_CR30","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.7150\/jca.32716","volume":"10","author":"G Long","year":"2019","unstructured":"Long G, Tang W, Fu X, Liu D, Zhang L, Hu G et al (2019) Pre-treatment serum lactate dehydrogenase predicts distant metastasis and poor survival in nasopharyngeal carcinoma. J Cancer 10(16):3657\u20133664. https:\/\/doi.org\/10.7150\/jca.32716","journal-title":"J Cancer"},{"issue":"35","key":"7809_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000004494","volume":"95","author":"M Zhang","year":"2016","unstructured":"Zhang M, Wei S, Su L, Lv W, Hong J (2016) Prognostic significance of pretreated serum lactate dehydrogenase level in nasopharyngeal carcinoma among Chinese population: a meta-analysis. Medicine (Baltimore) 95(35):e4494. https:\/\/doi.org\/10.1097\/md.0000000000004494","journal-title":"Medicine (Baltimore)"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-022-07809-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-022-07809-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-022-07809-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T17:17:22Z","timestamp":1680283042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-022-07809-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["7809"],"URL":"https:\/\/doi.org\/10.1007\/s00405-022-07809-6","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]},"assertion":[{"value":"5 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the Xiangya Hospital of Central South University prior to commencement [IRB number:  202208191] and was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}